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ABSTRACT
The HIV-1 viral infectivity factor (Vif) is required
for productive infection of non-permissive cells,
including most natural HIV-1 targets, where it coun-
teracts the antiviral activities of the cellular cytosine
deaminases APOBEC-3G (A3G) and A3F. Vif is a
multimeric protein and the conserved proline-rich
domain
161PPLP
164 regulating Vif oligomerization is
crucial for its function and viral infectivity. Here, we
expressed and purified wild-type Vif and a mutant
protein in which alanines were substituted for the
proline residues of the
161PPLP
164 domain. Using
dynamic light scattering, circular dichroism and
fluorescence spectroscopy, we established the
impact of these mutations on Vif oligomerization,
secondary structure content and nucleic acids
binding properties. In vitro, wild-type Vif formed
oligomers of five to nine proteins, while Vif AALA
formed dimers and/or trimers. Up to 40% of the
unbound wild-type Vif protein appeared to be
unfolded, but binding to the HIV-1 TAR apical loop
promoted formation of b-sheets. Interestingly,
alanine substitutions did not significantly affect the
secondary structure of Vif, but they diminished its
binding affinity and specificity for nucleic acids.
Dynamic light scattering showed that Vif oligomer-
ization, and interaction with folding-promoting
nucleic acids, favor formation of high molecular
mass complexes. These properties could be import-
ant for Vif functions involving RNAs.
INTRODUCTION
In addition to the three conserved retroviral protein pre-
cursors Gag, Pol and Env, the human immunodeﬁciency
virus type 1 (HIV-1) encodes several regulatory (Tat, Rev
and Nef) and auxiliary proteins (Vif, Vpr and Vpu), which
are known to modulate the host environment and regulate
the efﬁciency of viral replication and transmission (1).
The HIV-1 virion infectivity factor (Vif), is a 23kDa
basic protein of 192 amino acids (2) that is absolutely
required for productive infection of some cell types,
named ‘non-permissive’, such as primary T-cells, mono-
cytes and macrophages, (3–5). In those cells, Vif has been
shown to efﬁciently counteract the antiviral activity of
several APOBEC3 (APOlipoprotein B mRNA-editing
enzyme catalytic polypeptide-like) cytidine deaminases
by various mechanisms (6,7). Among the members of
this enzyme family, APOBEC3G (A3G) and A3F
display the highest antiviral activity (8–13). In the
absence of Vif, these antiviral factors are incorporated
into budding virions and promote cytosine deamination
during ( ) strand DNA synthesis. Besides, HIV-1 DNA
synthesis and integration can also be impaired by A3G/3F
irrespective of their catalytic activity, suggesting that de-
amination is not the only determinant for antiviral activity
(6,12,14–16). In non-permissive cells, Vif targets A3G/3F
for degradation by the proteasome by recruiting an E3
ubiquitin ligase cellular complex composed of Elongin B
(EloB), Elongin C (EloC), Cullin 5 (Cul5) and RING-box
protein 2 (Rbx2) (11,17–21). This is probably not the
only mechanism used by Vif to neutralize A3G/3F anti-
viral effects. Indeed, it was observed that Vif can also
(i) inhibit, directly or indirectly, packaging and antiviral
activity of a degradation resistant A3G mutant (22); (ii)
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mass (HMM) complexes (23) and (iii) reduce intracellular
expression of A3G (24,25). In this context, we recently
showed that Vif down regulates A3G translation by
binding to the 50-UTR region of its mRNA (26).
Vif protein consists in several functional domains
(Figure 1A). The N-terminal region corresponds to an
RNA-binding domain, and contains discontinuous
binding sites for A3G and A3F (17,27–31). Interestingly,
this domain is rich in highly conserved tryptophan
residues (32) that confer an intrinsic ﬂuorescence signal
to Vif. It has been shown that Vif possesses an RNA
chaperone activity (33) and binds speciﬁcally and coopera-
tively the 50-end region of HIV-1 genomic RNA in vitro
(34,35) and in infected cells (36,37). Next to these
RNA and A3G/3F binding domains, the HCCH motif
(residues 108–139) coordinates a Zn
2+ ion (Figure 1A).
This motif, together with the following highly conserved
144SLQYLA
149 domain (38) plays a crucial role in A3G/F
protein inactivation (39,40). Indeed, these regions
bind directly to Cul5 and EloBC factors (20,41,42)
(Figure 1A), leading to A3G/F degradation by the prote-
asome (43). Next, region 151–164 encompasses the
conserved proline-rich region
161PPLP
164 that governs
Vif multimerization (Figure 1A) (44,45). Indeed, Vif has
been shown to self-associate and to form dimers, trimers
and tetramers in vitro (44,46), as well as in cells (44). This
short domain was found to be crucial for Vif function and
viral infectivity (44,45,47). Moreover, it can interact with
A3G (48,49), Cul5 (39) and HIV-1 reverse transcriptase
(50). Recently, it was also observed that an intact PPLP
motif is required for interaction with EloB (51,52). In this
context, it is conceivable that these functions are linked to
the multimerization state of Vif. Finally, it was observed
that Vif exists in both membrane-associated and cytoplas-
mic forms (53), and mutagenesis studies demonstrate that
these functions could be attributed to the C-terminal basic
domain of Vif, which also interacts with the Pr55
Gag pre-
cursor (Figure 1A) (47,53,54).
In the cytoplasm, Vif was also found to be a component
of an RNP complex containing cellular and viral factors
like genomic RNA and Pr55
Gag (36,37,55). Interestingly,
these interactions with viral RNA and Pr55
Gag are respon-
sible for Vif incorporation into viral particles (55,56).
Moreover, Vif( ) virions are affected in their morphology
and reverse transcription (57,58). The deﬁciency in
proviral DNA synthesis could result from the destabiliza-
tion of the viral core, suggesting that Vif association to
RNA might mediate genome engagement with Pr55
Gag
precursor in the assembly complex (6,59).
While numerous studies contributed to investigate the
multiple functions of Vif, there is still a lack of informa-
tion concerning its tridimensional structure (43). To date,
the only available 3D structure corresponds to peptide
139–179 in association with an EloB/C complex (60).
Theoretical predictions provided structural information
on Vif domains, and homology models and disorder pre-
diction studies contributed to predict the overall tertiary
structure of N- and C-terminal domains (43,46,61,62).
Recently, other studies combining circular dichroism
(CD) and dynamic light scattering (DLS) provided con-
formational analysis of a peptide approximating the
HCCH motif (63,64) and the C-terminal domain of Vif
(65). Nevertheless, there still remains a lack of structural
information of Vif protein in its unbound state and in
interaction with nucleic acids, as well. One of the major
limitations resides in difﬁculties in expressing and purify-
ing full-length HIV-1 Vif proteins. Here, we described the
expression and puriﬁcation of wild-type HIV-1 Vif protein
and a mutant form in which the proline-rich domain
leading to Vif multimerization was replaced by alanines
(Vif AALA). Conformational investigations, secondary
Figure 1. (A) Schematic representation of HIV-1 Vif domains required for interactions with viral and cellular partners. (B) Secondary structure
of RNA sequences TAR, and its DNA analog, dTAR. Primary structure of fragment B2 encompassing genomic nucleotides 539–547, and its
DNA analog dB2.
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high-afﬁnity RNA and DNA sites were characterized by
biophysical techniques including DLS, CD and ﬂuores-
cence spectroscopy. We provide evidence of unstructured
regions in unbound Vif, and show that upon binding to
the HIV-1 TAR apical loop, the unfolded content of Vif
decreases. This was not the case for other primary binding
sites. Interestingly, the alanine substitutions in the Vif
PPLP motif did not signiﬁcantly affect the overall second-
ary structure of the protein, but it decreased the binding
afﬁnity and speciﬁcity for nucleic acids. Finally, con-
formational analysis of ribonucleoprotein complexes
showed that Vif oligomerization, as well as its binding
to folding-promoting nucleic acids, are required to
promote the formation of HMM complexes.
MATERIALS AND METHODS
Recombinant Vif proteins
Expression plasmids pD10WT-Vif or pD10AALA-Vif
were used to transform Escherichia coli BL21 cells as
described earlier (26). Brieﬂy, production of Vif proteins
was induced by addition of 0.5mM IPTG to log phase
bacterial cultures (OD600nm=0.4–0.6). After 6 h at 22 C
for wild-type Vif or at 16 C in the case of Vif AALA,
bacteria were harvested by centrifugation at 4000g
during 15min, lysed in the denaturating lysis buffer (6M
guanidine hydrochloride, 100mM sodium phosphate,
10mM Tris, pH 8) at room temperature and stirred over-
night. Cellular debris was separated by centrifugation at
27000g during 30min at 4 C and the cleared lysate was
loaded onto a Ni-NTA agarose column (Invitrogen). The
column was washed with the lysis buffer and elution was
performed by pH decreasing (from 6.5 to 4.5). Fractions
containing Vif proteins were analyzed on 12% SDS–
PAGE and pooled. Proteins were then renatured by
slow dialysis against buffers with decreasing guadinium
chloride concentration, and ﬁnally against a buffer con-
taining 50mM MOPS pH 6.5, 150mM NaCl, 10%
glycerol. This last buffer was supplemented with 550mM
arginine during the dialysis step to avoid the precipitation
of Vif AALA protein. As both wild-type Vif and Vif
AALA tend to aggregate, protein stock solutions were
centrifuged at 100000g for 30min at 4 C immediately
prior to use. The protein concentration in the supernatant
was determined spectrophotometrically and UV spectros-
copy revealed that puriﬁed Vif proteins were not
contaminated by nucleic acids.
Size exclusion chromatography
Gel ﬁltration chromatography was performed at 25 Co n
a Superdex 75 (Pharmacia) in an AKTA puriﬁer FPLC
(GE Healthcare Biosciences, UK). The running buffer was
50mM NaCl, 50mM MOPS, 10% glycerol, 0,5mM
Tween-80, 2mM DTT for wild-type Vif protein and
150mM NaCl, 50mM MOPS, 10% glycerol, 2mM
DTT for Vif AALA protein. The gel ﬁltration column
was calibrated in the different buffers used for analysis
with molecular mass markers (thyroglobulin 670kDa,
bovine g-globulin 158kDa, chicken ovalbumin 44kDa,
equine myoglobin 17kDa and vitamine B12 1350 Da).
Protein elution was monitored at 280nm and results
were analyzed using Unicorn software (version 4.11).
RNA and DNA oligonucleotides
Plasmid pHXB2 was used as a template to amplify 500bp
DNA fragments corresponding to the 50-UTR (RNA A), a
part of gag gene (RNA B), and 30-UTR (RNA H) regions
of the HIV-1 genome. Pairs of sense and antisense primers
were used in PCR reactions and products were digested
and inserted into pUC18 as described in ref. (34). Plasmids
were linearized and used as template for in vitro tran-
scription with bacteriophage T7 RNA polymerase.
Reaction mixture was incubated with RNase-free DNase
I (Qbiogen), extracted with phenol, and precipitated in
ethanol. RNAs were then puriﬁed by FPLC (Amersham
Biosciences Inc.) and dissolved in water.
Three RNA oligonucleotides corresponding to a
C10 sequence, the TAR apical loop and RNA B2
(a single-stranded sequence located between nucleotides
539 and 546 of the HIV-1 genomic RNA) (35) (Figure
1B) were synthesized by Microsynth (Balgach,
Switzerland) and puriﬁed by anion exchange HPLC
on a nucleo-PAC PA-100 column (Dionex Co). Their
DNA counterparts were synthesized and puriﬁed by
reverse-phase HPLC (ThermoFisher Scientiﬁc, Ulm-
Germany).
Diffusion light scattering
Wild-type Vif and Vif AALA samples were prepared
in 50mM MOPS, 150mM NaCl, pH 6.5 at a ﬁnal concen-
tration of 15mM. Intensities of scattered light and correl-
ation times were measured with a Zetasizer Nano S
(Malvern, UK). Measurements were performed in a
single 50ml trUView cuvette (Biorad Laboratories, CA,
USA), maintained at 25 C. Diffusion light scattering
(DLS) ﬂuctuations of the scattering intensity due to
Brownian motion were recorded atmicrosecond time inter-
vals. An autocorrelation function was derived, thus leading
to the determination of diffusion coefﬁcients. Assimilating
proteins in solution to spheres, diffusion coefﬁcients were
related to the hydrodynamic radius of the particles, Rh via
the Stokes–Einstein equation:
D ¼
kT
Rh6pm
ð1Þ
in which k is the Boltzmann constant, T the temperature
(K),m the solvent viscosity and D the translational diffu-
sion coefﬁcient. All experimental data were corrected
for solvent viscosity (measured with a 3.5ml micro-
Ubbelohde capillary viscosimeter tube from Schott,
Germany), and refractive index (measured with an Abbe ´
refractometer). Size measurements by DLS have been used
to monitor the assembly of Vif proteins and oligonucleo-
tides. Increasing amounts of nucleic acids (protein/nucleic
acid ratio, R varying from 0 to 2) were added to a ﬁxed
amount of wild-type Vif protein (between 10 and 15mM).
Scattering data of Vif proteins and protein/oligonucleotide
complexes were then analyzed using DLS analysis software
(Malvern, UK).
2406 Nucleic Acids Research, 2011,Vol.39, No. 6Circular dichroism
Wild-type Vif and Vif AALA (10mM) protein samples
were prepared anaerobically in 50mM MOPS, 150mM
NaCl, pH 6.5 at a ﬁnal concentration of 15mM. Far-UV
CD spectra (190–250nm) were measured in a Jasco J-810
spectropolarimeter (Jasco Inc., Easton, MD, USA).
Samples were placed in rectangular quartz cuvettes of
2-mm path length maintained at 20 C. Spectra were
acquired at 50nm/min with a time constant of 1s and
band-width equal to 1. Each spectrum represents the
average of 15 successive baseline-corrected scans.
The mean residue molar ellipticity [] was determined ac-
cording to:
 ½  ¼   MR ðÞ =ð10       cÞð 2Þ
where  is the measured ellipticity in millidegrees, MR
is the mean residue mass,   the optical path length and
c, the protein concentration. For wild-type Vif, equimol-
ecular amounts of nucleic acid were added directly in the
cell measure. Corresponding spectra were corrected for
nucleic acids absorbance and ellipticity. Deconvolution
of far-UV CD spectra and consequent secondary structure
of proteins content was estimated by Dichroweb (http://
dichroweb.cryst.bbk.ac.uk/html/home.shtml).
Steady state ﬂuorescence measurements
Fluorescence measurements were recorded in quartz cells
at 20±0.2 C on a Fluoromax-4 ﬂuorometer (HORIBA
Jobin-Yvon Inc., NJ, USA). The excitation wavelength
was set at 295nm for selective excitation of Trp residues.
The emission wavelength was scanned from 310 to
450nm; the integration time was 0.1s, and the excitation
and emission bandwidths were 5nm. Fluorescence titra-
tions were performed by adding increasing amounts of
nucleic acid to 100nM Vif in 30mM Tris–HCl (pH 7.5),
200mM NaCl and 10mM MgCl2. Fluorescence intensities
were corrected for buffer ﬂuorescence and dilution effect.
To determine the binding parameters of Vif proteins
to genomic RNA fragments, we measured the decrease
of the ﬂuorescence intensity, I, at a ﬁxed concentration
of protein in presence of increasing RNA concentrations.
The ﬂuorescence intensity was then converted into the
intrinsic ﬂuorescence quenching Qobs:
Qobs ¼
I0   I
I0
ð3Þ
with I0 corresponding to the protein ﬂuorescence intensity
in absence of nucleic acid.
Scatchard equation was used to ﬁt the protein/nucleic
acid titration data (66):
  ¼
nK obsL
1+Kobs L
ð4Þ
where L corresponds to the free protein concentration
which is obtained by:
L ¼ Lt   vNt ð5Þ
Finally, the average number v of protein bound per
oligonucleotides was determined using:
  ¼
ðI0   IÞ
ðI0   IfÞ
Lt
Nt
ð6Þ
where Lt and Nt correspond to the total concentration of
protein and oligonucleotide, respectively, and If is the
ﬂuorescence intensity at the plateau when all the proteins
are bound to the nucleic acid.
The model of McGhee and von Hippel for cooperative
binding (67), was used to ﬁt protein/genomic RNA
fragment titration data:
v
L
¼ Kobs   1   nv ðÞ
  
2!   1 ðÞ ð 1   nvÞ+v   R ½ 
n 1
2 !   1 ðÞ ð 1   nvÞ ½ 
n 1  
1   n+1 ðÞ v+R ½ 
2
21  nv ðÞ ½ 
2
ð7Þ
with R ¼ 1   n+1 ðÞ v ½ 
2+4!v 1   nv ðÞ
 1=2
Where n corresponds to the number of consecutive nu-
cleotides occluded upon binding of one ligand, and o,t o
the cooperativity parameter. Because the McGhee and
von Hippel (67) model was derived with the simplifying
assumption of an inﬁnite lattice of binding sites, we
introduced a correction factor taking into account the
ﬁnite lattice size, N. The correction merely amounts to
multiplying Equation 7 by the factor (N n+1) / (N) (68).
Curve ﬁtting was performed using Mathematica software
(Wolfram Research Inc, Champaign, IL, USA).
RESULTS
The PPLP motif contributes to Vif oligomerization
We ﬁrst focused on Vif protein characterization, and in
particular, we wished to establish the impact of the PPLP
motif on Vif self-association. Prior to each analysis,
proteins were centrifuged as described (26) and soluble
fractions were used to determine the oligomerization
state of the proteins by size exclusion chromatography
and DLS. Wild-type Vif protein had an apparent molecu-
lar weight of 209kDa (Figure 2A), as judged by its elution
volume from the size exclusion chromatography column
(11.25ml), suggesting that Vif is organized as a complex
of about nine proteins (Figure 2C). On the contrary, Vif
AALA assembles as a complex of 76kDa (Figure 2B),
thus containing about three proteins (Figure 2C). Next,
we characterized Vif proteins by DLS. Assuming that Vif
proteins in solution can be considered as spherical par-
ticles, the diffusion coefﬁcient could be related to their
hydrodynamic radius via the Stokes–Einstein equation
(Equation1). For wild-type Vif, we observed a mean
radius of 5.3±0.6nm (Figure 3A), which corresponds
to about 5–8 Vif proteins. Differently, Vif AALA
mutant protein showed a mean radius of 3.2±0.3nm,
which can most likely be assigned to protein dimers
(Figure 3B). Altogether, both techniques gave similar
results and showed that proline to alanine substitutions
strongly reduce the capacity of Vif to multimerize, and
Nucleic Acids Research,2011, Vol.39, No. 6 2407Figure 2. Size exclusion chromatography on wild-type and mutant Vif proteins. Elution proﬁles of Vif wild-type (A) and Vif AALA (B) are
represented together with protein standards. (C) The molecular weights (log) are plotted against elution volumes calibrated using molecular
weight standards. Measured molecular weights of Vif wild-type and Vif AALA give 209kDa and 76kDa, respectively, corresponding to about
9 and 3 Vif proteins in each complex.
Figure 3. Diffusion light scattering proﬁles of wild-type Vif (A) and Vif AALA (B) proteins. (A) Mean radius for wild-type protein was 5.3±0.6nm,
which corresponds to polymers containing 5 to 8 Vif proteins. (B) Vif AALA proteins showed a mean radius of 3.2±0.3nm, mainly corresponding
to dimers of Vif.
2408 Nucleic Acids Research, 2011,Vol.39, No. 6demonstrate that the PPLP motif contributes to the
oligomerization of the Vif protein. However, the mutant
protein was still able to dimerize, indicating that other
regions of Vif also contribute to multimerization.
The oligomerization state of Vif inﬂuences neither its
secondary structure nor its ﬂuorescence properties
Because amino acid changes can often affect secondary
structure of proteins, we next analyzed wild-type and Vif
AALA proteins by UV-CD spectroscopy to determine
their secondary structural content. Analysis of the
UV-CD spectrum for wild-type protein revealed that
the HIV-1 Vif contains 41.5% b-sheet, 6.5% a-helix,
40% random coil, and the remaining 12% are turns
(Figure 4A). The secondary structure content of Vif
AALA protein was rather similar: we observed nearly
identical fractions of b-sheet (42%) and random coil
(46%), and a slight decrease in a-helical content (5%),
and turns (7%). Taken together these data suggest that
mutation of the proline-rich domain in Vif does not sig-
niﬁcantly affect the overall secondary structure of the
protein (Figure 4A).
Trp residues constitute very sensitive probes for
investigating protein/nucleic acid interactions because of
their high quantum yield and sensitivity to the physico-
chemical environment (69). Vif contains six Trp residues
in its N-terminal domain, which corresponds to the RNA
binding region (37) (Figure 1A). We have observed earlier
that after selective excitation of Trp residues at 295nm,
the emission spectrum revealed a maximum at 338nm
(35). Vif AALA presented its maximal emission at
340nm (Figure 4B). Free Trp amino acid in solution dis-
played a ﬂuorescence emission maximum at 350nm, and
the blue shifts of the emission maximum of wild-type and
Vif AALA revealed that Trp residues in both proteins
are mainly located in a non-polar environment (70).
This shows that mutation of the Vif PPLP motif does
not signiﬁcantly interfere with the local environment of
Trp residues. Moreover, upon nucleic acid binding, the
wavelength of maximal ﬂuorescence emission of Vif
AALA was unchanged, whereas the ﬂuorescence intensity
decreased depending on the nucleic acid sequences and
concentration (Figure 4B).
Mutation of the PPLP motif of Vif decreases its
afﬁnity and speciﬁcity toward HIV-1 RNA
We showed earlier that Vif is an RNA binding protein
that binds speciﬁcally the 50-terminal region of HIV-1
genomic RNA (34,35). Here, we asked whether Vif
multimerization is involved in this process. To this aim,
we synthesized in vitro a set of genomic RNA fragments
of  500nt in length corresponding to parts of the gag
coding regions (RNA A and RNA B) or containing the
polypurine tract (PPT), which constitutes the primer for
(+) strand DNA synthesis during reverse transcription
(RNA H) (Table 1) (34). Reverse titrations were per-
formed by adding small volumes of concentrated RNA
solutions to a ﬁxed amount of protein, and protein
binding was monitored through the decrease of Vif
AALA intrinsic ﬂuorescence resulting from protein/
nucleic acid complex formation. According to our earlier
results (35), best ﬁt of our experimental data was obtained
with a cooperative model (Equation 7) (67). Fluorescence
titrations revealed a decrease of Vif AALA ﬂuorescence of
 70–75% (Table 1). Analysis of the equilibrium dissoci-
ation constants, Kd, showed that Vif AALA had a similar
afﬁnity for RNA fragments A, B and H (Table 1). In
addition, protein binding to RNAs A and B was moder-
ately more cooperative (o  85–110) compared with
binding to RNA H (o  65). Finally, the binding stoichi-
ometry of Vif AALA, given by the intersection of the
initial slope of the titration curves with the ﬂuorescence
plateau (data not shown), was about 10 Vif proteins for all
RNAs. On the opposite, wild-type Vif protein displayed
higher ﬂuorescence quenching, afﬁnity and binding
cooperativity values for RNAs A and B (Qmax  77%,
Kd  45–55nM, and o  65–80) compared with RNA H
(Qmax   47%, Kd  165nM, o  17) (35). Moreover,  45
wild-type Vif proteins bound to RNAs A and B, and
about 20 bound to RNA H (35). Taken together these
results suggest that mutation of the PPLP motif
Figure 4. Inﬂuence of Vif oligomerization on its secondary structure
content and ﬂuorescence properties. (A) Far-UV-CD spectra of
wild-type (green) and AALA mutant (blue) Vif proteins. Proteins
were prepared at a ﬁnal concentration of 10mM. (B) Emission ﬂuores-
cence spectra of free Trp amino acid (dashed line), free Vif AALA
protein in solution (solid line) and in complex with TAR fragment
(dotted line). Excitation wavelength was set at 295nm.
Nucleic Acids Research,2011, Vol.39, No. 6 2409signiﬁcantly decreases the overall afﬁnity and speciﬁcity of
Vif for viral RNA.
Vif AALA has lower afﬁnity than wild-type Vif for
minimal nucleic acids
We previously identiﬁed and characterized several
minimal high afﬁnity binding sites of wild-type Vif to
HIV-1 RNA fragments (35). Here, we analyzed the
binding of Vif AALA to two of them: the apical region
of the trans-activation responsive element (TAR), a stable
stem-loop structure located at the 50-end of the viral
genome (71), and a single-stranded segment (B2) en-
compassing nucleotides 539–547 of HIV-1 gag gene
(Figure 1B). As a negative control, we analyzed Vif
AALA binding to a C10 oligonucleotide, which was
shown earlier to bind modestly wild-type Vif protein
(35). According to our previous experiments (35), we
expected that only one protein would bind to these oligo-
nucleotides, and thus experimental data were ﬁtted with a
model for non-interacting ligands to a ﬁnite lattice
(Equation 4) (66). Data analysis revealed very similar
binding parameters for TAR and B2 oligoribonucleotides
(Kd  32–37nM, Table 2). Compared with wild-type
protein, Vif AALA presented 3 to 4-fold lower afﬁnity
for TAR and oligo B2 (Kd  9.5–13nM, Table 2) (35).
However, both proteins showed very similar equilibrium
dissociation constants for C10 (Kd  60nM, Table 2). We
next extended our analysis to DNA counterparts of these
RNA minimal binding sites (Figure 1B). Indeed Vif
binding to DNA sequences might protect HIV-1 genome
by neutralizing A3G/3F antiviral activity by competition
mechanisms (34). Analysis of dissociation constants of Vif
AALA for dTAR and dB2 showed similar Kd values (Kd
 36 39nM, Table 2) compared with their RNA analogs,
and 3- to 4-fold weaker afﬁnities (Kd  9.5–11nM,
Table 2) compared with the wild-type protein (35).
Finally, the afﬁnity of Vif AALA for dC10 was almost
2-fold lower than the ones observed for dTAR and dB2
oligonucleotides (Table 2). Compared with the wild-type
protein, Vif AALA showed a weaker afﬁnity for speciﬁc
RNA and DNA binding sites, indicating that the PPLP
motif plays a signiﬁcant role in the speciﬁcity of inter-
action with nucleic acids.
Interaction of wild-type Vif with RNAs promoting
protein folding is a determinant of HMM complex
formation
We next analyzed the secondary structure content of
wild-type Vif protein in association with equimolecular
amount of RNA and DNA oligonucleotides. Corres-
ponding CD spectra were ﬁrst corrected for nucleic acids
absorbance and ellipticity before analysis. When TAR
oligoribonucleotide was added to wild-type Vif, changes
in CD spectra indicated a signiﬁcant decrease in random
coil content (from 40% to 19%) and turns (from 12% to
7%,), while b-sheets secondary structures increased from
41.5% to 69.5% (Table 3), and proportion of a-helical
forms slightly decreased (from 6.5% to 4.5%). Vif
binding to B2 oligoribonucleotide was characterized by a
2-fold decrease of turns (12–6%) and a slight decrease in
a-heliticity (2.5%); however, this was offset by a moderate
increase in b-sheet (41.5–46%) and random coil (40–44%)
content. Binding to C10 RNA gave only very slight
changes in protein secondary structure content (Table 3).
On the contrary, when dTAR was added to Vif protein,
the changes in CD spectra indicated an increase in
structured content (a-heliticity from 6.5% to 10%, and
b-sheet from 41.5% to 54%, Table 3), in parallel to a
decrease of turns and random coils (12% to 6% and
40% to 30%, respectively). In agreement with results
obtained with RNA oligonucleotides, Vif binding to dB2
led to a moderate increase in secondary structure content.
Table 1. Vif AALA and wild-type VIF binding parameters RNA
genomic fragments
RNA Genomic
region
VIF AALA HIV-1 VIF
Kd (nM)
a o
a Q% Kd
b o
b Q%
b
A 1–497 40±7 107±28 71 57±7 68±4 76
B 499–996 37±4 85±15 75 45±4 80±3 77
H 8625–9181 56±9 60±11 71 167±6 17±3 47
The maximum ﬂuorescence quenching, Qmax, the cooperativity param-
eter, o, and the equilibrium dissociation constants, Kd were obtained as
described under ‘Materials and Methods’ section.
aMean±SD of at least three experiments.
bBinding parameters relative to wild-type Vif protein and genomic
RNA fragments were published earlier in reference (35).
Table 2. Characterization of Vif AALA and wild–type VIF binding
to RNA and DNA oligonucleotides
VIF AALA HIV-1 VIF
Ksca (nM)
a Ksca (nM)
a
RNA DNA RNA DNA
TAR/dTAR 37±1 36±1 9.5±2.2
b 9.5±2.3
b
B2/dB2 32±2 39±2 13±2
b 11±2
b
C10/dC10 61±2 69±2 59±3 48±2
b
Determination of the apparent dissociation constants (Ksca) of Vif
proteins was realized using the Scatchard model (66)
aMean±SD of at least three experiments.
bBinding parameters relative to wild-type Vif protein and RNA/DNA
oligonucleotides were previously published in reference (35).
Table 3. Determination of secondary structure contents of wild-type
Vif protein bound to RNA and DNA oligonucleotides
R a-helical (%) b-sheet (%) Turns (%) Random (%)
0 6.5 41.5 12 40
TAR 1 4.5 69.5 7 19
B2 1 4 46 6 44
C10 1 5 41 11 43
dTAR 1 10 54 6 30
dB2 1 8 45 12 35
dC10 1 6 40 12 42
Equimolecular amounts of nucleic acids were added to wild-type Vif
protein (R=1). Spectra were corrected for nucleic acids ellipticity.
2410 Nucleic Acids Research, 2011,Vol.39, No. 6Finally, binding to dC10 produced only minor structural
changes (Table 3).
We further characterized ribonucleoprotein complexes
by DLS. Vif proteins were mixed with increasing amount
of TAR and B2 oligoribonucleotides (molar ratio R varied
between 0 and 2) and we measured the hydrodynamic
radius of the complex. In the case of wild-type Vif
protein, at the highest R-value, Vif/TAR complexes were
characterized by a mean radius almost 2-fold higher than
the one measured for Vif/B2 complexes under the same
conditions (Figure 5). On the contrary, in the case of
Vif AALA, the radius of ribonucleoprotein complexes
was similar for TAR and B2 sequences. Moreover, as
expected from its oligomerization defect, the average size
of Vif AALA/RNA complexes was lower than the one
observed for wild-type Vif protein at equivalent molar
ratio (Figure 5). Taken together, these results are consist-
ent with a model where binding of Vif to speciﬁc RNA
binding sites, such as the TAR element, may help the
protein to adopt a more structured, and probably func-
tional, conformation. Moreover oligomerization and
interaction with nucleic acids that induce protein folding
are important determinants for the formation of HMM
ribonucleoprotein complexes.
DISCUSSION
HIV-1 Vif protein has been shown to form oligomers both
in vitro and in vivo (44,46). The multimerization of Vif
involves a sequence mapping between residues 151 to
164 in the C-terminal domain, and more precisely the
161PPLP
164 motif (44,45). Interestingly, disruption of this
domain inhibited A3G degradation, and consequently
increased its incorporation into viral particles, resulting
in a loss of viral infectivity (44,48,49). Recently the
PPLP motif was found to be required for the assembly
of an active E3 ubiquitin ligase complex by interacting
with the C-terminal domain of EloB (51,52). In this
context, the oligomerization of Vif mediated by its
proline-rich motif appears as an interesting target for de-
veloping therapeutic anti-HIV-1 drugs.
In this work, we expressed and puriﬁed wild-type HIV-1
Vif protein and a Vif mutant in which proline residues in
the
161PPLP
164 domain were replaced by alanines. In order
to precisely establish the impact of these mutations on Vif
oligomerization, conformation and nucleic acids binding
properties, we ﬁrst characterized the oligomerization state
of Vif proteins. Assuming that proteins in solution can be
assimilated to spherical particles, we could determine their
hydrodynamic radius by DLS. This analysis conﬁrmed
that in vitro wild-type Vif forms multimers containing
5–8 proteins (Figure 3A) (44,46). The same analysis
applied to Vif AALA revealed that mutation of residues
161–164 mainly resulted in the formation of Vif dimers
(Figure 3B). These results are in good agreement with
the average molecular weight of wild-type Vif and Vif
AALA determined by size exclusion chromatography
(Figure 2), which showed that the two proteins could be
organized as a complex of about 9 and 3 proteins, respect-
ively (Figure 2C). Hence, even if oligomerization is con-
siderably diminished in mutated proteins, it is not
completely abolished, suggesting that regions outside the
PPLP domain are also involved in protein–protein associ-
ation. In this context, conformational analysis of a peptide
corresponding to the HCCH motif of HIV-1 Vif showed
that this Zn-binding domain could induce protein–protein
interactions upon zinc binding. Indeed, metal binding
increased formation of b-sheets, thus promoting protein
self-association (63).
To gain insight into the secondary structure content
of wild-type and mutant Vif proteins, we performed
near-UV-CD spectroscopy. We observed that wild-type
Vif contains nearly identical amounts of b-sheet (41.5%)
and random coil (40%), only 6.5% a-helices and 12% of
turns (Figure 4 and Table 3). The presence of large
unfolded regions in Vif protein is consistent with
previous studies, which provided evidence for the unstruc-
tured nature of its unbound C-terminal domain
Figure 5. Ribonucleoprotein complexes were characterized by DLS. Increasing concentration of wild-type Vif were added to various amounts of
oligoribonucleotides TAR and B2 (R RNA/protein ratio varying between 0 and 2). Similarly, TAR and B2 were added to Vif AALA. Protein/nucleic
acid complex formation resulted in increasing complex radius.
Nucleic Acids Research,2011, Vol.39, No. 6 2411(46,61,65,72). Natively unfolded regions confer high net
charge and low overall hydrophobicity to proteins (73).
Moreover, these unstructured domains are usually useful
to mediate sequential/differential binding with multiple
partners by inducing conformational changes for speciﬁc
interaction (74,75). Indeed, it has recently been shown that
intrinsic unstructured regions of Vif could be important
for its interaction with an E3 ubiquitin ligase complex (64)
and with EloC, resulting in this case in a-helix folding
(51,60). Similar analysis on Vif AALA showed that both
proteins have very similar secondary structure content,
indicating that mutation of the proline-rich domain,
which induces substantial changes of Vif quaternary struc-
ture, does not signiﬁcantly affect its overall secondary or-
ganization (Figure 4).
Cross-linking experiments showed that contrary to
the mainly unfolded C-terminal region, the N-terminal
domain possesses a well-deﬁned topology (46). This
domain contains highly conserved tryptophan residues
(32) that allowed us to compare ﬂuorescence proﬁles of
free Trp amino acids in solution (70), and Trp residues in
Vif AALA (Figure 4B) and wild-type Vif proteins (35).
Our results showed similar burial of those residues in
wild-type and mutant proteins, suggesting that modiﬁca-
tion of the oligomerization state of Vif does not interfere
with local environment of Trp residues, and consequently
on the tertiary structure of Vif N-terminal domain.
However, the replacement of prolines by alanines
reduced the tendency of Vif to oligomerize in favor of
protein dimers. Proline residues are known to form
bends and kinks in proteins, and the PPLP motif could
behave as a hinge between Vif domains leading to protein
self-association. Our data support the idea that structural
domains of Vif likely fold independently of each other,
since alanine substitutions did not affect secondary
and tertiary structure of the adjacent Vif domains.
Moreover, the increased ﬂexibility of the protein
backbone due to alanine replacement would probably
modify reciprocal spatial orientation of protein domains
thus diminishing Vif tendency to oligomerization.
We previously showed that Vif speciﬁcally interacts
with the 50-region of HIV-1 genomic RNA (34,35) and
with A3G mRNA (26). In particular, Vif binding to the
50-UTR of A3G mRNA might be crucial for down-
regulating A3G translation and may participate, together
with the proteasome pathway, in reducing its intracellular
level. Moreover, the RNA chaperone activity of Vif was
found to potentially inﬂuence temporal regulation of
HIV-1 genomic RNA dimerization and reverse transcrip-
tion (33). These results suggest that RNA binding plays a
crucial role in Vif functions. In order to evaluate the inci-
dence of Vif multimerization on its RNA binding
properties, we characterized binding properties of Vif
AALA to RNA fragments corresponding to various
regions of HIV-1 genomic RNA (Table 1) and to previ-
ously identiﬁed high afﬁnity binding sites (Table 2) (35).
Globally, binding parameters analysis showed that alter-
ation of the Vif PPLP domain reduces the overall afﬁnity
and speciﬁcity for RNAs (Tables 1 and 2). Similar results
were obtained when analyzing Vif AALA binding to DNA
counterparts of the primary TAR and B2 binding sites
(Table 2). These results are in agreement with a recent
study showing that Vif AALA binds to A3G mRNA frag-
ments with lower afﬁnity and speciﬁcity (26). This loss of
speciﬁcity and afﬁnity for nucleic acid binding might affect
functions of Vif that are based on RNA interactions, such
as particle assembly and reverse transcription (55,58,76).
In this regard, it was observed that mutations reducing
Vif afﬁnity for RNA, diminished viral replication in
non-permissive cells (37).
Vif binding to the upper TAR stem-loop induces a sig-
niﬁcant folding of the protein (Table 3). Interestingly,
increasing the b-sheet fraction could expose hydrophobic
surfaces, and thus promote protein–protein interactions.
DLS experiments on wild-type Vif associated to TAR
showed HMM complexes likely induced by protein oligo-
merization. Remarkably, Vif association with oligonucleo-
tide B2, which has a similar afﬁnity for Vif (35), did not
lead to a signiﬁcant increase of secondary structure
content (Table 3). Accordingly, the size of the Vif/B2
complexes showed a mean radius 2-fold lower than the
one measured for Vif/TAR under the same conditions
(Figure 5). Thus, it is possible that the nucleic acid
length inﬂuences Vif oligomerization (77). These results
also would suggest the existence of a class of nucleic
acid partners, which increases protein structure content
upon binding and induces formation of HMM
ribonucleoprotein complexes. Indeed, binding afﬁnity
should not be a determinant for this mode of protein/
RNA interaction. Besides, different Vif/nucleic acids
binding modes could correspond to different functions
played by the protein during HIV-1 infection. We have
previously proposed that Vif binding to viral RNA or
DNA fragments could protect the genome from A3G/3F
editing by a direct competition with these antiviral factors
(35). Thus, despite the limited amount of Vif into viral
particles, this tendency to oligomerization and to form
ribonucleoprotein complexes would allow Vif to cover
and protect viral nucleic acids. Moreover, we recently
observed that mutations of the domain governing Vif
multimerization reduced the overall afﬁnity of the
protein for A3G mRNA, but interestingly, without affect-
ing its translation (26). Considering these new results, it
would be conceivable that wild-type Vif would make use
of this binding mode to inhibit ribosome scanning.
Further in vivo studies would deﬁnitively shed light on
molecular mechanisms involving the ability of Vif to
bind nucleic acids and to form HMM ribonucleoprotein
complexes. Unfortunately, we were not able to purify Vif
AALA protein in sufﬁcient amounts and under the con-
ditions required for the CD analysis of protein/nucleic
acid complexes. Nevertheless DLS analysis on Vif
AALA binding to TAR and B2 sequences showed a
similar size of ribonucleoprotein complexes in both
cases. However, compared with wild-type protein, the
average size of the protein/RNA complexes was almost
5-fold lower (Figure 5), thus conﬁrming that multi-
merization facilitates the formation of HMM
ribonucleoprotein complexes.
Beyond the genomic RNA context, Vif could make use
of this property to oligomerize and form ribonucleo-
protein complexes to target A3G. Indeed, A3G was
2412 Nucleic Acids Research, 2011,Vol.39, No. 6found to accumulate into punctate cytoplasmic structures
described as P bodies or stress bodies (78–80), and analysis
of cell lysates revealed the assembly of this antiviral
factor into HMM complexes (81). Interestingly, mass
spectrometry of immuno-puriﬁed HMM complexes
identiﬁed a multi-subunit ribonucleoprotein complex
(78,79,82) containing various RNAs such as A3G
mRNA, and HIV-1 Gag mRNA in infected cells (79).
Interestingly, Vif induces conversion of A3G low molecu-
lar mass complexes to presumably packaging-incompetent
HMM complexes in cells (81,83,84). Beside Vif activities
in A3G degradation (11,17,18,20,21,85) and inhibition of
A3G translation (24–26), this sequestration mechanism
would represent another mechanism to limit the antiviral
effect of A3G. Taken together, our results indicate that
Vif multimerization could be important for functions
involving RNAs, such as viral particle assembly and
reverse transcription or A3G binding and degradation
(49,86). Thus, dissecting the molecular mechanisms
regulating Vif–RNA interactions, including protein oligo-
merization, could provide novel targets for rational drugs
design against HIV-1. Finally, the analysis of wild-type
and mutant Vif proteins performed in this study provide
information about the multimerization stage, the presence
of unfolded regions, and the binding to ligands that are
crucial for any attempt to solve a 3D protein structure
by NMR or X-ray crystallography.
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